News | September 15, 2020

CuraSen Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial with First Proprietary Compound, CST-2032, Targeting Neurodegenerative Disease Novel Approach Aimed at Restoring Brain Functionality September 15, 2020 — San Mateo, Calif.—CuraSen...

News | September 15, 2020

Adventist Health Enhances Online Access for Both New and Existing Patients with Kyruus and Cerner Collaboration by Kyruus, on Sep 15, 2020 9:00:00 AM California-Based Health System is First to Offer Kyruus ProviderMatch® Integrated with the Cerner Consumer FrameworkTM...

News | August 10, 2020

Saniona successfully raises USD 65 million (approximately SEK 567 million) in a directed issue of shares NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE...

News | September 14, 2020

ESCAPE BIO CLOSES $73 MILLION IN CROSSOVER FINANCING TO ADVANCE CLINICAL DEVELOPMENT OF PRECISION NEUROLOGY MEDICINES FOR GENETIC NEURODEGENERATION – ESCAPE BIO SOUTH SAN FRANCISCO, September 14, 2020 — ESCAPE Bio, a clinical stage company developing novel, precisely...

News | August 4, 2020

ReViral Announces FDA Fast Track Designation Granted to Sisunatovir For The Treatment of Serious Respiratory Syncytial Virus Infection London, UK, and Research Triangle Park, NC, August 4, 2020 – ReViral Ltd., a clinical-stage biopharmaceutical company focused on...

News | July 24, 2020

Approval based on Phase III ETHOS trial which showed a statistically significant reduction in the rate of exacerbations compared with dual-combination therapies AstraZeneca’s Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) has been approved in the...